MA29540B1 - Comprime drageifie - Google Patents

Comprime drageifie

Info

Publication number
MA29540B1
MA29540B1 MA30465A MA30465A MA29540B1 MA 29540 B1 MA29540 B1 MA 29540B1 MA 30465 A MA30465 A MA 30465A MA 30465 A MA30465 A MA 30465A MA 29540 B1 MA29540 B1 MA 29540B1
Authority
MA
Morocco
Prior art keywords
coating
drageified
compressor
active ingredient
stabilized
Prior art date
Application number
MA30465A
Other languages
English (en)
Inventor
Yoshihiro Uchiyama
Yoshinori Nakano
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37498554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29540(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA29540B1 publication Critical patent/MA29540B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION CONCERNE UNE PRÉPARATION PHARMACEUTIQUE DANS LAQUELLE UN PRINCIPE ACTIF INSTABLE EN PRÉSENCE D'OXYGÈNE EST STABILISÉ EN ENROBANT UNE PORTION CONTENANT LEDIT PRINCIPE ACTIF AVEC UNE COUCHE D¿ENROBAGE EN SUCRE CONTENANT (1) UN ALCOOL GLUCIDIQUE EN TANT QUE BASE D'ENROBAGE ET (2) UN LIANT.
MA30465A 2005-06-10 2007-12-10 Comprime drageifie MA29540B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005171443 2005-06-10

Publications (1)

Publication Number Publication Date
MA29540B1 true MA29540B1 (fr) 2008-06-02

Family

ID=37498554

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30465A MA29540B1 (fr) 2005-06-10 2007-12-10 Comprime drageifie

Country Status (19)

Country Link
US (1) US20090030064A1 (fr)
EP (1) EP1889611A1 (fr)
JP (1) JPWO2006132360A1 (fr)
KR (1) KR20080014014A (fr)
CN (1) CN101193625A (fr)
AR (1) AR054133A1 (fr)
AU (1) AU2006256038A1 (fr)
BR (1) BRPI0611058A2 (fr)
CA (1) CA2610342A1 (fr)
CR (1) CR9523A (fr)
IL (1) IL187407A0 (fr)
MA (1) MA29540B1 (fr)
NO (1) NO20080175L (fr)
NZ (1) NZ563820A (fr)
PE (1) PE20070077A1 (fr)
RU (1) RU2407515C2 (fr)
TW (1) TW200716207A (fr)
WO (1) WO2006132360A1 (fr)
ZA (1) ZA200710333B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009101940A1 (fr) * 2008-02-11 2009-08-20 Dainippon Sumitomo Pharma Co., Ltd. Comprimé présentant des propriétés d'élution améliorées
TW201021832A (en) * 2008-09-30 2010-06-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
JPWO2011027728A1 (ja) * 2009-09-02 2013-02-04 日本曹達株式会社 ヒドロキシアルキルセルロースを含むコーティング剤
CN101804042A (zh) * 2010-04-16 2010-08-18 山东新华制药股份有限公司 普拉格雷片剂的制备方法
US10251194B2 (en) * 2013-06-17 2019-04-02 Nxp Usa, Inc. Efficient scheduling in asynchronous contention-based system
FR3013186B1 (fr) * 2013-11-19 2019-07-19 Roquette Freres Nouveaux snacks non allergenes contenant des proteines vegetales
CN103977427A (zh) * 2014-05-08 2014-08-13 王�琦 一种糖衣产气粉配方及其制备方法
FR3067567B1 (fr) * 2017-06-19 2019-07-05 Roquette Freres Nouveau procede de drageification et formes solides drageifiees presentant des formes irregulieres
FR3089756B1 (fr) * 2018-12-17 2021-02-19 Roquette Freres Formes solides dragéifiées présentant une stabilité améliorée
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1168082A (fr) * 1979-10-17 1984-05-29 Francis Devos Procede de revetement rigide avec le sorbitol et produits ainsi obtenus
JPH0816052B2 (ja) * 1988-11-21 1996-02-21 エスエス製薬株式会社 糖衣錠
JP3507211B2 (ja) * 1995-07-13 2004-03-15 三菱化学株式会社 糖衣液及び糖衣錠
PT1136477E (pt) * 1998-12-04 2004-08-31 Takeda Chemical Industries Ltd Derivados do benzofurano processo para a sua preparacao e suas utilizacoes
JP2001139495A (ja) * 1999-11-19 2001-05-22 Shin Etsu Chem Co Ltd フィルムコーティング剤及び経口固形製剤
AT500063A1 (de) * 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
JP2002047174A (ja) * 2000-05-26 2002-02-12 Towa Chem Ind Co Ltd 無糖コーティング製剤及びその製造方法
DE10033023A1 (de) * 2000-07-07 2002-01-31 Biogrund Gmbh Filmüberzugszusammensetzung auf Basis von Zellulosederivaten und Zuckeralkoholen
JP2002179559A (ja) * 2000-10-06 2002-06-26 Takeda Chem Ind Ltd 薄層糖衣錠およびその製造方法
JP4824224B2 (ja) * 2001-08-28 2011-11-30 興和株式会社 糖衣製剤
JP2003095928A (ja) * 2001-09-27 2003-04-03 Kowa Co 糖衣製剤
JP2003113060A (ja) * 2001-10-02 2003-04-18 Lion Corp 発泡成分含有糖衣物
JP4336074B2 (ja) * 2001-11-15 2009-09-30 三菱商事フードテック株式会社 色調および食感が良好な硬質糖衣錠剤
US20050118202A1 (en) * 2001-12-19 2005-06-02 Akio Yamashita Solid compositions containing compounds unstable to oxygen and method for stabilization thereof
JP4590034B2 (ja) * 2002-01-31 2010-12-01 三菱商事フードテック株式会社 硬質糖衣製剤、糖衣液及び硬質糖衣製剤の製造方法
JP2004123578A (ja) * 2002-09-30 2004-04-22 Dainippon Ink & Chem Inc 糖衣錠およびその製造方法
JP2005298373A (ja) * 2004-04-08 2005-10-27 Kyowa Hakko Kogyo Co Ltd 吸水性アミノ酸含有糖衣錠剤
JP4984455B2 (ja) * 2004-08-18 2012-07-25 日本新薬株式会社 二重被覆錠剤

Also Published As

Publication number Publication date
AU2006256038A1 (en) 2006-12-14
KR20080014014A (ko) 2008-02-13
BRPI0611058A2 (pt) 2011-02-22
JPWO2006132360A1 (ja) 2009-01-08
EP1889611A1 (fr) 2008-02-20
WO2006132360A1 (fr) 2006-12-14
CN101193625A (zh) 2008-06-04
CR9523A (es) 2008-02-04
NZ563820A (en) 2010-03-26
TW200716207A (en) 2007-05-01
RU2007145426A (ru) 2009-06-20
CA2610342A1 (fr) 2006-12-14
PE20070077A1 (es) 2007-02-07
ZA200710333B (en) 2009-03-25
RU2407515C2 (ru) 2010-12-27
NO20080175L (no) 2008-03-04
US20090030064A1 (en) 2009-01-29
IL187407A0 (en) 2008-02-09
AR054133A1 (es) 2007-06-06

Similar Documents

Publication Publication Date Title
Garibov et al. Synthesis of 4, 5-disubstituted-2-thioxo-1, 2, 3, 4-tetrahydropyrimidines and investigation of their acetylcholinesterase, butyrylcholinesterase, carbonic anhydrase I/II inhibitory and antioxidant activities
Price et al. Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice
Damin-Pernik et al. Management of rodent populations by anticoagulant rodenticides: toward third-generation anticoagulant rodenticides
Simon et al. Early lipopolysaccharide-induced reactive oxygen species production evokes necrotic cell death in human umbilical vein endothelial cells
Singab et al. Hypoglycemic effect of Egyptian Morus alba root bark extract: effect on diabetes and lipid peroxidation of streptozotocin-induced diabetic rats
Kim et al. Antihepatotoxic activity of bergenin, the major constituent of Mallotus japonicus, on carbon tetrachloride-intoxicated hepatocytes
CN103153946B (zh) 外周限制性 faah 抑制剂
Gros et al. Evaluation of azasterols as anti-parasitics
MA35430B1 (fr) Procédés de réduction du taux de lipoprotéine(a) par l'administration d'un inhibiteur de proprotéine convertase subtilisine/kexine-9 (pcsk9)
Röcken et al. Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation
Kalimeris et al. N-acetylcysteine ameliorates liver injury in a rat model of intestinal ischemia reperfusion
Chen et al. Evaluation of gender-related differences in various oxidative stress enzymes in mice
Dzhemilev et al. Short route to the total synthesis of natural muricadienin and investigation of its cytotoxic properties
Gocer et al. Spirobisnaphthalenes effectively inhibit carbonic anhydrase
Simplicio et al. Contribution of oxidative stress and prostanoids in endothelial dysfunction induced by chronic fluoxetine treatment
Tai et al. Endogenous molecules stimulating N-acylethanolamine-hydrolyzing acid amidase (NAAA)
Paino et al. Effect of therapeutic plasma concentrations of non-steroidal anti-inflammatory drugs on the production of reactive oxygen species by activated rat neutrophils
Ježek et al. Aglycemic HepG2 cells switch from aminotransferase glutaminolytic pathway of pyruvate utilization to complete Krebs cycle at hypoxia
Staub et al. Mechanism for benomyl action as a mitochondrial aldehyde dehydrogenase inhibitor in mice
Sayin et al. Antioxidant and Anti-Atherogenic Properties of Hawthorn Vinegar in Drosophila melanogaster Fed a High-Fat Diet.
ATE388143T1 (de) Cumarin derivate und ihre verwendung als anticoagulantien
Ciftci et al. Beta-glucan prevents toxic effects of 2, 3, 7, 8-TCDD in terms of oxidative and histopathological damage in heart tissue of rats
Sharma et al. 5‐arylidene‐2, 4‐thiazolidinediones as cysteine protease inhibitors against Leishmania donovani
Ito et al. Fenitrothion action at the endocannabinoid system leading to spermatotoxicity in Wistar rats
Tasdemir Type II fatty acid biosynthesis, a new approach in antimalarial natural product discovery